<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35212063</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><Volume>291</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations.</ArticleTitle><Pagination><StartPage>801</StartPage><EndPage>812</EndPage><MedlinePgn>801-812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.13458</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and are related to long-term respiratory dysfunction remains unknown.</AbstractText><AbstractText Label="METHODS">Plasma was collected during hospital admission and after 3 months from the NOR-Solidarity trial (n = 181) and analyzed for markers of gut barrier dysfunction and inflammation. At the 3-month follow-up, pulmonary function was assessed by measuring the diffusing capacity of the lungs for carbon monoxide (DL<sub>CO</sub> ). Rectal swabs for gut microbiota analyses were collected (n = 97) and analyzed by sequencing the 16S rRNA gene.</AbstractText><AbstractText Label="RESULTS">Gut microbiota diversity was reduced in COVID-19 patients with respiratory dysfunction, defined as DL<sub>CO</sub> below the lower limit of normal 3 months after hospitalization. These patients also had an altered global gut microbiota composition, with reduced relative abundance of 20 bacterial taxa and increased abundance of five taxa, including Veillonella, potentially linked to fibrosis. During hospitalization, increased plasma levels of lipopolysaccharide-binding protein (LBP) were strongly associated with respiratory failure, defined as pO<sub>2</sub> /fiO<sub>2</sub> (P/F ratio) &lt;26.6 kPa. LBP levels remained elevated during and after hospitalization and were associated with low-grade inflammation and respiratory dysfunction after 3 months.</AbstractText><AbstractText Label="CONCLUSION">Respiratory dysfunction after COVID-19 is associated with altered gut microbiota and persistently elevated LBP levels. Our results should be regarded as hypothesis generating, pointing to a potential gut-lung axis that should be further investigated in relation to long-term pulmonary dysfunction and long COVID.</AbstractText><CopyrightInformation>&#xa9; 2022 The Association for the Publication of the Journal of Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vestad</LastName><ForeName>Beate</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7934-4751</Identifier><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian PSC Research Center, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueland</LastName><ForeName>Thor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerum</LastName><ForeName>T&#xf8;ri Vigeland</ForeName><Initials>TV</Initials><Identifier Source="ORCID">0000-0001-8326-9993</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Oslo University Hospital Ullev&#xe5;l, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Tuva B&#xf8;rresdatter</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care and Emergencies, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian PSC Research Center, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barratt-Due</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Critical Care and Emergencies, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Immunology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xe5;sine</LastName><ForeName>Trine</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0868-9861</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care and Emergencies, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyrhol-Riise</LastName><ForeName>Anne Ma</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiksrud</LastName><ForeName>Birgitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonby</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoel</LastName><ForeName>Hedda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Department, Lovisenberg Diaconal Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Inge Christoffer</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriksen</LastName><ForeName>Katerina Nezvalova</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Haematology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Pharmacies, South-Eastern Norway Enterprise, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tveita</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Department, Baerum Hospital, Vestre Viken Hospital Trust, Drammen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manotheepan</LastName><ForeName>Ravinea</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Medicine, Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haugli</LastName><ForeName>Mette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, S&#xf8;rlandet Hospital SSK, Kristiansand, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiken</LastName><ForeName>Ragnhild</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Innlandet Hospital Trust, Lillehammer, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>&#xc5;se</ForeName><Initials>&#xc5;</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Bente</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lekva</LastName><ForeName>Tove</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranheim</LastName><ForeName>Trine</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michelsen</LastName><ForeName>Annika Elisabeth</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kildal</LastName><ForeName>Anders Benjamin</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, University Hospital of North Norway, Troms&#xf8;, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannessen</LastName><ForeName>Asgeir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thoresen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ringerike Hospital, Vestre Viken Hospital Trust, Ringerike, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skudal</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Telemark Hospital Trust, Skien, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kittang</LastName><ForeName>B&#xe5;rd Reiakvam</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Roy Bj&#xf8;rkholt</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Sorlandet Hospital, Arendal, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ystr&#xf8;m</LastName><ForeName>Carl Magnus</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Innlandet Hospital Trust, Elverum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skei</LastName><ForeName>Nina Vibeche</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Levanger Hospital, Nord-Tr&#xf8;ndelag Hospital Trust, Levanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannula</LastName><ForeName>Raisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aballi</LastName><ForeName>Saad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, &#xd8;stfold Hospital Kalnes, Gr&#xe5;lum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kv&#xe5;le</LastName><ForeName>Reidar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skj&#xf8;nsberg</LastName><ForeName>Ole Henning</ForeName><Initials>OH</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Oslo University Hospital Ullev&#xe5;l, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aukrust</LastName><ForeName>P&#xe5;l</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hov</LastName><ForeName>Johannes Roksund</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian PSC Research Center, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Gastroenterology, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tr&#xf8;seid</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NOR-Solidarity study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012336">RNA, Ribosomal, 16S</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012336" MajorTopicYN="N">RNA, Ribosomal, 16S</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">pulmonary function</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35212063</ArticleId><ArticleId IdType="pmc">PMC9115297</ArticleId><ArticleId IdType="doi">10.1111/joim.13458</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Galanopoulos M, Gkeros F, Doukatas A, Karianakis G, Pontas C, Tsoukalas N, et&#xa0;al. Covid&#x2010;19 pandemic: pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020;26(31):4579&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445869</ArticleId><ArticleId IdType="pubmed">32884218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic features of COVID&#x2010;19: a concise review. Pathol Res Pract. 2020;216(9):153097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334952</ArticleId><ArticleId IdType="pubmed">32825963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira C, Viana SD, Reis F. Gut microbiota dysbiosis&#x2010;immune hyperresponse&#x2010;inflammation triad in coronavirus disease 2019 (COVID&#x2010;19): impact of pharmacological and nutraceutical approaches. Microorganisms. 2020;8(10):1514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7601735</ArticleId><ArticleId IdType="pubmed">33019592</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignesh R, Swathirajan CR, Tun ZH, Rameshkumar MR, Solomon SS, Balakrishnan P. Could perturbation of gut microbiota possibly exacerbate the severity of COVID&#x2010;19 via cytokine storm? Front Immunol. 2020;11:607734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7868418</ArticleId><ArticleId IdType="pubmed">33569053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et&#xa0;al. Alterations in gut microbiota of patients with COVID&#x2010;19 during time of hospitalization. Gastroenterology. 2020;159(3):944&#x2013;55.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Dweep H, Yin X, Wang H, Damra M, Goldman AR, et&#xa0;al. Plasma markers of disrupted gut permeability in severe COVID&#x2010;19 patients. Front Immunol. 2021;12:686240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219958</ArticleId><ArticleId IdType="pubmed">34177935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoel H, Heggelund L, Reikvam DH, Stiksrud B, Ueland T, Michelsen AE, et&#xa0;al. Elevated markers of gut leakage and inflammasome activation in COVID&#x2010;19 patients with cardiac involvement. J Intern Med. 2021;289(4):523&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536991</ArticleId><ArticleId IdType="pubmed">32976665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et&#xa0;al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314193</ArticleId><ArticleId IdType="pubmed">32497191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, et&#xa0;al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID&#x2010;19. Gut. 2021;70(4):698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao&#x2010;Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, et&#xa0;al. Repurposed antiviral drugs for COVID&#x2010;19&#x2014;interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt&#x2010;Due A, Olsen IC, Nezvalova&#x2010;Henriksen K, K&#xe5;sine T, Lund&#x2010;Johansen F, Hoel H, et&#xa0;al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID&#x2010;19: a randomized trial. Ann Intern Med. 2021;174:1261&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279143</ArticleId><ArticleId IdType="pubmed">34251903</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et&#xa0;al. 2017 ERS/ATS standards for single&#x2010;breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49(1):1600016.</Citation><ArticleIdList><ArticleId IdType="pubmed">28049168</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et&#xa0;al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794117</ArticleId><ArticleId IdType="pubmed">31613151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerum TV, Aalokken TM, Bronstad E, Aarli B, Ikdahl E, Lund KMA, et&#xa0;al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID&#x2010;19. Eur Respir J. 2021;57(4):2003448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736755</ArticleId><ArticleId IdType="pubmed">33303540</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler SA, Ebner L, Aubry&#x2010;Beigelman C, Bridevaux P&#x2010;O, Brutsche M, Clarenbach C, et&#xa0;al. Pulmonary function and radiological features 4 months after COVID&#x2010;19: first results from the national prospective observational Swiss COVID&#x2010;19 lung study. Eur Respir J. 2021;57(4):2003690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082329</ArticleId><ArticleId IdType="pubmed">33419891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerum TV, Maltzahn NN, Aukrust P, Tr&#xf8;seid M, Henriksen KN, K&#xe5;sine T, et&#xa0;al. Persistent pulmonary pathology after COVID&#x2010;19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase&#x2010;9. Sci Rep. 2021;11(1):23205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636497</ArticleId><ArticleId IdType="pubmed">34853380</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW, et&#xa0;al. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J. 2017;50(3):1700010.</Citation><ArticleIdList><ArticleId IdType="pubmed">28893868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadrosh DW, Ma B, Gajer P, Sengamalay N, Ott S, Brotman RM, et&#xa0;al. An improved dual&#x2010;indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome. 2014;2(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3940169</ArticleId><ArticleId IdType="pubmed">24558975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummen M, Holm K, Anmarkrud JA, Nyg&#xe5;rd S, Vesterhus M, H&#xf8;ivik ML, et&#xa0;al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66(4):611&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26887816</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi M, Vestad B, Hansen SH, Holm K, Drivsholm N, Goetz A, et&#xa0;al. Impact of human immunodeficiency virus&#x2014;related gut microbiota alterations on metabolic comorbid conditions. Clin Infect Dis. 2020;71:e359&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">31894240</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, Boribong BP, et&#xa0;al. Multisystem inflammatory syndrome in children is driven by zonulin&#x2010;dependent loss of gut mucosal barrier. J Clin Invest. 2021;131:e149633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279585</ArticleId><ArticleId IdType="pubmed">34032635</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K, et&#xa0;al. Gut microbiota diversity predicts immune status in HIV&#x2010;1 infection. AIDS. 2015;29(18):2409&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">26355675</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen SF, Troseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, et&#xa0;al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. 2016;9(6):1455&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">26982597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweigner J, Schumann RR, Weber JR. The role of lipopolysaccharide&#x2010;binding protein in modulating the innate immune response. Microbes Infect. 2006;8(3):946&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16483818</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavamani A, Salem I, Sferra TJ, Sankararaman S. Impact of altered gut microbiota and its metabolites in cystic fibrosis. Metabolites. 2021;11(2):123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7926988</ArticleId><ArticleId IdType="pubmed">33671639</ArticleId></ArticleIdList></Reference><Reference><Citation>Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, et&#xa0;al. Intestinal inflammation in children with cystic fibrosis is associated with Crohn's&#x2010;like microbiota disturbances. J Clin Med. 2019;8(5):645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6572243</ArticleId><ArticleId IdType="pubmed">31083321</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, et&#xa0;al. Analysis of the intestinal microbiota in COVID&#x2010;19 patients and its correlation with the inflammatory factor IL&#x2010;18. Med Microecol. 2020;5:100023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832617</ArticleId><ArticleId IdType="pubmed">34173452</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira GLV, Oliveira CNS, Pinzan CF, de Salis LVV, Cardoso CRB. Microbiota modulation of the gut&#x2013;lung axis in COVID&#x2010;19. Front Immunol. 2021;12:635471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7945592</ArticleId><ArticleId IdType="pubmed">33717181</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneaux PL, Cox MJ, Willis&#x2010;Owen SA, Mallia P, Russell KE, Russell A&#x2010;M, et&#xa0;al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299577</ArticleId><ArticleId IdType="pubmed">25184687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayerhofer CCK, Kummen M, Holm K, Broch K, Awoyemi A, Vestad B, et&#xa0;al. Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail. 2020;7:456&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160496</ArticleId><ArticleId IdType="pubmed">31978943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>